Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled study of filgotinib for active non-infectious uveitis
MOH_2017-11-12_001914Phase 2Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in noninfectious uveitis (NIU), Hyalitis, posterior uveitis and 1 more comparing Filgotinib 200 mg with Placebo (2 arms). Primary endpoint: Primary endpoint not reported. Planned start Nov 2017; status: not yet recruiting.
02
Drugs
filgotinib
03
Conditions
noninfectious uveitis (NIU)Hyalitisposterior uveitispanuveitis
Beyond the preview
Go deeper on MOH_2017-11-12_001914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-11-12_001914.